EGFR and cancer: Network pharmacology analysis indicated that 22 key metabolites in wild soybeans were associated with 503 pan-cancer targets (covering breast, lung, and colorectal cancers), primarily regulating pathways related to "cancer" and "lipids and atherosclerosis." Molecular docking experiments further confirmed the stable binding affinity of key bioactive components, including quercetin and L-arginine, with core targets such as TP53, TNF, EGFR, IL1B, and JUN.